Pradhan Akshyaya, Tiwari Ashish, Sethi Rishi
Department of Cardiology, King George's Medical University, Lucknow, India.
Int J Hypertens. 2019 Nov 3;2019:1824621. doi: 10.1155/2019/1824621. eCollection 2019.
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.
高血压仍然是一种全球性的流行病，给卫生系统带来了巨大的死亡率、发病率和经济负担。不幸的是，大多数高血压患者最终需要联合使用两种或更多药物才能达到其目标血压（BP）。为此，更有效的抗高血压药物的出现是一个好迹象。血管紧张素受体阻滞剂（ARB）是日常高血压管理的基石。在所有ARB中，迄今为止，阿齐沙坦在大多数头对头试验中被证明更有效。阿齐沙坦是最新获批用于高血压治疗的ARB，效力更强且副作用最小。本综述重点介绍了阿齐沙坦在当代高血压管理中的作用。
